Objective: To investigate the relationship between the single ALT positive (ELSIA-HBV/HCV negative) and NAT-HBV/HCV on blood donor samples. Methods: 28710 samples were surveyed retrospectively from Dec. 2010 to Dec. 2...Objective: To investigate the relationship between the single ALT positive (ELSIA-HBV/HCV negative) and NAT-HBV/HCV on blood donor samples. Methods: 28710 samples were surveyed retrospectively from Dec. 2010 to Dec. 2011. ALT was detected by rate method, and the single ALT positive samples were detected by ELSIA-HBV/HCV and NAT-HBV/HCV. The relationship between the single ALT positive and NAT-HBV/HCV were analyzed. 21 samples, values in 40 U/L ≤ ALT ≤ 70 U/L, were selected at random from 2516 samples with single ALT positive, which were second detected by ELISA and NAT in the second donation. Results: 2516 (8.74%) single ALT positive samples (ELSIA-HBV/HCV negative) were found in 28710 donors. Among these samples, 8 (2.8/10000) positive were detected by NAT, including 5 HBV-DNA-positive and 3 HCV-RNA-positive. Obviously, positive rate of NAT from the donors whose ALT value ≤ 70 U/L were lower than those of ≥ 71 U/L (P < 0.01). 21 donors were investigated in the second donation in following 153 to 401 days, All samples were negative by ELISA-HBV/HCV and NAT-HBV/HCV. Conclusions: Donors with single ALT positive (value in 40 U/L-70 U/L) are not likely to become HBV/HCV virus carriers or HBV/HCV patients after half or one year. So it is to set ALT abandone threshlod to ≤ 70 U/L can ensure blood safety, and reduce blood abandone in our center.展开更多
The study included 200 thalassemia patients, 120 （60%） males and 80 （40%） females, at age 2-30 years the mean age 16 years and 100 persons from blood donors at age 20-50 years, the mean age 35 years, as control gr...The study included 200 thalassemia patients, 120 （60%） males and 80 （40%） females, at age 2-30 years the mean age 16 years and 100 persons from blood donors at age 20-50 years, the mean age 35 years, as control group. The authors used ELISA HCV 3.0 to detect anti-HCV in serum of thalassemia patients and blood donors. The results show 17% positive, 76% negative and 7% equivocal in serum ofthalassemia patients, but show 1% positive, 98% negative, 1% equivocal in serum of blood donors. The results show significant difference in P ≤ 0.05 between prevalence of anti-HCV antibodies among thalassemia patients and blood donors, the confirmatory tests by recombinant immunoblot assay version 3.0 （RIBA） show 17.5% positive, 79% negative and 3.5% equivocal in serum of thalassemia patients but show 2% positive, 98% negative in serum of blood donors. The thalassemia patients in the present study region had high seroprevalence of anti-HCV.展开更多
文摘Objective: To investigate the relationship between the single ALT positive (ELSIA-HBV/HCV negative) and NAT-HBV/HCV on blood donor samples. Methods: 28710 samples were surveyed retrospectively from Dec. 2010 to Dec. 2011. ALT was detected by rate method, and the single ALT positive samples were detected by ELSIA-HBV/HCV and NAT-HBV/HCV. The relationship between the single ALT positive and NAT-HBV/HCV were analyzed. 21 samples, values in 40 U/L ≤ ALT ≤ 70 U/L, were selected at random from 2516 samples with single ALT positive, which were second detected by ELISA and NAT in the second donation. Results: 2516 (8.74%) single ALT positive samples (ELSIA-HBV/HCV negative) were found in 28710 donors. Among these samples, 8 (2.8/10000) positive were detected by NAT, including 5 HBV-DNA-positive and 3 HCV-RNA-positive. Obviously, positive rate of NAT from the donors whose ALT value ≤ 70 U/L were lower than those of ≥ 71 U/L (P < 0.01). 21 donors were investigated in the second donation in following 153 to 401 days, All samples were negative by ELISA-HBV/HCV and NAT-HBV/HCV. Conclusions: Donors with single ALT positive (value in 40 U/L-70 U/L) are not likely to become HBV/HCV virus carriers or HBV/HCV patients after half or one year. So it is to set ALT abandone threshlod to ≤ 70 U/L can ensure blood safety, and reduce blood abandone in our center.
文摘The study included 200 thalassemia patients, 120 （60%） males and 80 （40%） females, at age 2-30 years the mean age 16 years and 100 persons from blood donors at age 20-50 years, the mean age 35 years, as control group. The authors used ELISA HCV 3.0 to detect anti-HCV in serum of thalassemia patients and blood donors. The results show 17% positive, 76% negative and 7% equivocal in serum ofthalassemia patients, but show 1% positive, 98% negative, 1% equivocal in serum of blood donors. The results show significant difference in P ≤ 0.05 between prevalence of anti-HCV antibodies among thalassemia patients and blood donors, the confirmatory tests by recombinant immunoblot assay version 3.0 （RIBA） show 17.5% positive, 79% negative and 3.5% equivocal in serum of thalassemia patients but show 2% positive, 98% negative in serum of blood donors. The thalassemia patients in the present study region had high seroprevalence of anti-HCV.
